A Study to Evaluate Intact FGF23 Performance in Patients with Tumor-induced Osteomalacia (TIO) and X-linked Hypophosphatemia (XLH)

Overview

About this study

The purpose of this study is to establish the clinical performance of the Medfrontier Intact FGF23 immunoassay in patients with tumor induced osteomalacia (TIO) and X-linked hypophosphatemia (XLH).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Patients with hypophosphatemia or suspected tumor induced osteomalacia (TIO) or suspected or confirmed X-linked hypophosphatemia (XLH).

Exclusion Criteria:

Patients with iron deficiency and chronic kidney disease as these patients might have elevations of FGF23.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Alicia Algeciras-Schimnich, Ph.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Alicia Algeciras-Schimnich, Ph.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials